605 related articles for article (PubMed ID: 19779305)
21. Primary sclerosing cholangitis.
Esber EJ; Ferguson DR
Gastroenterologist; 1994 Jun; 2(2):131-46. PubMed ID: 8055238
[TBL] [Abstract][Full Text] [Related]
22. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer.
Linder S; Söderlund C
Hepatogastroenterology; 2001; 48(38):387-92. PubMed ID: 11379315
[TBL] [Abstract][Full Text] [Related]
23. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
Al Mamari S; Djordjevic J; Halliday JS; Chapman RW
J Hepatol; 2013 Feb; 58(2):329-34. PubMed ID: 23085647
[TBL] [Abstract][Full Text] [Related]
24. Recent insights in primary sclerosing cholangitis.
Ponsioen CY
J Dig Dis; 2012 Jul; 13(7):337-41. PubMed ID: 22713082
[TBL] [Abstract][Full Text] [Related]
25. Primary sclerosing cholangitis.
Karlsen TH; Schrumpf E; Boberg KM
Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):655-66. PubMed ID: 20955968
[TBL] [Abstract][Full Text] [Related]
26. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
Lindor KD
N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
[TBL] [Abstract][Full Text] [Related]
27. Cholangiographic findings in deteriorating primary sclerosing cholangitis.
Van Laethem JL; Devière J; Bourgeois N; Love J; Gelin M; Cremer M; Adler M
Endoscopy; 1995 Mar; 27(3):223-8. PubMed ID: 7664699
[TBL] [Abstract][Full Text] [Related]
28. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
29. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
30. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
31. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
32. Small-duct primary sclerosing cholangitis with hepatocellular carcinoma requiring liver transplantation.
Ali S; Shah V
Hepatobiliary Pancreat Dis Int; 2010 Apr; 9(2):208-12. PubMed ID: 20382595
[TBL] [Abstract][Full Text] [Related]
33. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
34. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
35. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma.
Barr Fritcher EG; Kipp BR; Voss JS; Clayton AC; Lindor KD; Halling KC; Gores GJ
Am J Gastroenterol; 2011 Nov; 106(11):2023-8. PubMed ID: 21844920
[TBL] [Abstract][Full Text] [Related]
36. [Cholangiocarcinoma in primary sclerosing cholangitis: "chronicle of a death foretold"?].
Margalit M; Elinav H; Goldin E; Ilan Y
Harefuah; 2003 Jun; 142(6):421-5, 486. PubMed ID: 12858825
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
38. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation.
Nashan B; Schlitt HJ; Tusch G; Oldhafer KJ; Ringe B; Wagner S; Pichlmayr R
Hepatology; 1996 May; 23(5):1105-11. PubMed ID: 8621141
[TBL] [Abstract][Full Text] [Related]
39. Primary sclerosing cholangitis: summary of a workshop.
LaRusso NF; Shneider BL; Black D; Gores GJ; James SP; Doo E; Hoofnagle JH
Hepatology; 2006 Sep; 44(3):746-64. PubMed ID: 16941705
[TBL] [Abstract][Full Text] [Related]
40. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study.
Fevery J; Henckaerts L; Van Oirbeek R; Vermeire S; Rutgeerts P; Nevens F; Van Steenbergen W
Liver Int; 2012 Feb; 32(2):214-22. PubMed ID: 21745316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
